Volume 19, Number 3—March 2013
Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010
|Assumed proportion subclinical cases||No. clinical cases prevented (range)|
|30% (base estimate)||1,029,157 (712,908–1,458,930)|
*Data reflect calculations made for scenario 8 by changing assumed percentages of subclinical cases of influenza.
1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.
- Page created: February 12, 2013
- Page last updated: February 12, 2013
- Page last reviewed: February 12, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)